Finobrate 160 Tablet contains Fenofibrate 160mg, a lipid-lowering agent primarily used to manage hyperlipidemia and hypertriglyceridemia. Fenofibrate belongs to the fibrate class of medications and works by activating peroxisome proliferator-activated receptor alpha (PPARα), which plays a crucial role in regulating lipid metabolism. This activation leads to increased oxidation of fatty acids, reduced production of triglycerides, and enhanced clearance of low-density lipoprotein (LDL) cholesterol, thereby improving overall lipid profiles. Finobrate 160 is commonly prescribed to patients with elevated triglycerides and cholesterol levels who are at risk of cardiovascular diseases such as atherosclerosis, pancreatitis, and coronary artery disease. It is often used alongside dietary modifications and lifestyle changes, including exercise and weight management, to achieve optimal lipid control. The tablet is generally well-tolerated, but some patients may experience side effects such as gastrointestinal discomfort, muscle pain, or elevated liver enzymes. Regular monitoring of liver function and kidney function tests is recommended during therapy. Finobrate 160 should be used under medical supervision, especially in patients with pre-existing liver or kidney conditions, and is contraindicated in those with gallbladder disease or hypersensitivity to fenofibrate.